Negi, Sushmita and Tandel, Nikunj and Sharma, Prakriti and Kumar, Rajinder and Tyagi, Rajeev K (2023) Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation. Drug Discov. Today, 28 (8). p. 103671.
Full text not available from this repository. (Request a copy)Abstract
Rheumatoid arthritis (RA) is an inflammatory, autoimmune and connective-tissue arthropathy. The methotrexate (MTX) and aceclofenac (ACL) combination drug regimen is known to regulate the immunological pathways. Also, RA-elicited inflammation is decreased by the combination drug treatment. ACL and MTX combination treatment has been shown to regulate the signaling pathway controlled by NF-κB and FOXO1. The present manuscript reviews the importance of the combination drug regimen to treat and/or manage RA. The combination drug regimen could affect the Th1/Th17 axis to switch the balance toward the immunoregulatory (Th1) phenotype for establishing immune homeostasis. In conclusion, we propose the study of the immunological signaling pathways in experimental humanized RA mice.
| Item Type: | Article |
|---|---|
| Additional Information: | Copyright of this article belongs to Elsevier BV |
| Uncontrolled Keywords: | Methotrexate; aceclofenac; combination drug regimen; humanized mice; inflammation; nanoparticle; rheumatoid arthritis |
| Subjects: | Q Science > QR Microbiology |
| Depositing User: | Dr. K.P.S.Sengar |
| Date Deposited: | 25 Mar 2026 02:09 |
| Last Modified: | 25 Mar 2026 02:09 |
| URI: | http://crdd.osdd.net/open/id/eprint/3377 |
Actions (login required)
 |
View Item |
